Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q

被引：20
|
作者：
Starczynowski, Daniel T.
Karsan, Aly [1 ]
机构：
[1] BC Canc Agcy, Genome Sci Ctr, Vancouver, BC, Canada
来源：
CELL CYCLE | 2010年 / 9卷 / 05期
基金：
加拿大健康研究院;
关键词：
innate immunity; myelodysplastic syndromes; RPS14; FLI1; microRNAs; NF kappa B; IDENTIFICATION; 5Q-SYNDROME;
D O I：
10.4161/cc.9.5.11156
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：855 / 856
页数：2
相关论文
共 50 条
  • [41] Chromosome 5q subtelomeric deletion syndrome
    Rauch, Anita
    Doerr, Helmuth-Guenther
    AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2007, 145C (04) : 372 - 376
  • [42] Cytogenetics of myelodysplastic syndromes and detection of del 5q
    Mufti, G.
    LEUKEMIA RESEARCH, 2007, 31 : S8 - S9
  • [43] Suspected Immune Thrombocytopenic Purpura Induced by Lenalidomide for the Treatment of Myelodysplastic Syndrome with Deletion of Chromosome 5q: A Case Report
    Furukawa, Haruna
    Nomura, Jun
    Kobayashi, Masahiro
    Abe, Shori
    Takeda, Tomoki
    Oka, Yumiko
    Shirota, Yuko
    Kodera, Takao
    Okitsu, Yoko
    Takahashi, Shinichiro
    Murakami, Keigo
    Kameoka, Junichi
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2023, 259 (02): : 113 - 119
  • [44] Cryptic 5q deletion in a patient with myelodysplastic syndrome
    Medlock, Ruth
    Barrans, Sharon
    Cargo, Catherine
    Kelly, Richard
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (03) : 347 - 347
  • [45] Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
    Prebet, Thomas
    Cluzeau, Thomas
    Park, Sophie
    Sekeres, Mikkael A.
    Germing, Ulrich
    Ades, Lionel
    Platzbecker, Uwe
    Gotze, Katharina
    Vey, Norbert
    Oliva, Esther
    Sugrue, Mary M.
    Bally, Cecile
    Kelaidi, Charikleia
    Al Ali, Najla
    Fenaux, Pierre
    Gore, Steven D.
    Komrokji, Rami
    ONCOTARGET, 2017, 8 (47) : 81926 - 81935
  • [46] Attenuated familial adenomatous polyposis in a man with an interstitial deletion of chromosome arm 5q
    Pilarski, RT
    Brothman, AR
    Benn, P
    Rosengren, SS
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1999, 86 (04): : 321 - 324
  • [47] Efficacy of lenalidomide for treatment of anemia in secondary myelodysplastic syndrome (MDS) with chromosome 5q deletion
    Mintzer, David Michael
    Billet, Shira N.
    BLOOD, 2007, 110 (11) : 226B - 226B
  • [48] Marked elliptocytosis in myelodysplastic syndromes (MDS) is associated to deletion of chromosome 20q.
    Baweja, M
    Moreno-Aspitia, A
    Menke, DM
    Roy, V
    Zubair, A
    BLOOD, 2005, 106 (11) : 311B - 312B
  • [49] Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein, Elan
    Weber, Urs M.
    Gore, Steven
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (03) : 233 - 239
  • [50] Tifab, a Novel Candidate Gene in Deletion Chromosome 5q, Contributes to Deregulation of NF-κB Signaling in MDS/AML.
    Varney, Melinda
    Jerez, Andres
    Fang, Jing
    Miller, David
    Bolanos, Lyndsey
    Karsan, Aly
    Maciejewski, Jaroslaw P.
    Starczynowski, Daniel T.
    BLOOD, 2012, 120 (21)
12345